Characterization of insulin-like growth factor hinding proteins and regulation of IGFBP3 in human mesangial cells. IGF-I regulates renal growth and development. Insulin-like growth factor binding proteins (IGFBPs) are synthesized by the kidney and may modulate the local autocrine and/or paracrine actions of IGF-I. We have previously demonstrated that mesangial cells (MC) release IGF-l and IGF-binding activity; however, the specific IGFBPs produced by these cells and the factors involved in their regulation are unknown. We examined MC for expression of IGFBP-1 to -6 mRNAs and proteins. RNase protection assays using total RNA demonstrated that MC express all of the IGFBPs. E5251]IGFJ Western ligand blot of conditioned medium demonstrated that MC release IGFBPs of 24, 29, 32 kDa, and a doublet at 46 kDa, consistent with IGFBP-4, -5, -2 and -3, respectively. IGFBP species of 28 and 34 kDa were also detected. Since IGF-I and TGF-3 arc implicated in glomerular hypertrophy and matrix expansion, we tested their effect on IGFBPs released by MC. IGF-I (100 ng./ml), TGF-f3 (2 ng/ml) and forskolin (10-i at) differentially regulated the abundance of IGFBPs released in the conditioned medium in a time-dependent manner. IGF-I and TGF-beta were potent inducers of the release of IGFBP3 protein; however, TGF-j3, but not IGF-I, increased IGFBP3 mRNA levels. Recombinant IGFBP3 was tested for its effect on IGF-l-induced mitogenesis. IGFBP3 inhibited IGF-I-stimulated DNA synthesis in a dose-dependent manner with a peak effect observed at 50 nM IGFBP3. Although TGF-f3 is a potent inhibitor of IGF-I-stimulated DNA synthesis, this effect is not mediated via IGFBPs.
TGF-/3 to enhance extracellular matrix deposition within the glomerulus.
The biologic action of IGF-I/II in the kidney may be modulated by a family of six IGFBPs, designated IGFBP-1 to -6. These
IGFBPs bind with high affinity to lOP-I and -II, but not to insulin [11] . They serve as a reservoir and prolong the biologic half-life of TOPs in the circulation. Depending on the IGFBP species, target cell and culture conditions, IGPBPs may either inhibit IGF action by forming inactive complexes with IGFs or enhance TOP action by facilitating IGF interaction with surface receptors [12] . Certain TGFBPs provide a storage site for IGFs in the extraeellular matrix [13] . In addition, IGFBP-3 and -5 have intrinsic biologic activity independent of IGFs [14, 15] . IGPBPs are abundant in the human kidney and demonstrate distinct cellular distribution. By in situ hybridization, IGFBP-1 to -5 mRNAs arc expressed in glomeruli; however, the precise IGFBPs produced by the different cell types that comprise the glomerulus have not been determined [16] . We have previously demonstrated that human mesangial cells express lOP-I mRNA, lOP-I receptors and release IGF-I and IGF-binding activity [17] . These cells provide a useful model for determining the spectrum of IGFBPs released by mesangial cells, the factors that regulate IGFBP gene expression, and the role of each IGFBP in modulating lOP action in the glomerulus. Previous studies have demonstrated that adenylate cyclase agonists such as forskolin, and cytokines including IGF-I and TOF-J3, regulate IOFBPs in fibroblasts and other cell types [18] [19] [20] .
In this study, we determined the molecular identity of each IGFBP released by human mesangial cells. The effect of IGF-I, TOP-f3 and the cAMP agonist, forskolin, on IGFBPs released by mesangial cells was determined. Since IGFBP3 was markedly induced by lOP-I and TGF-3, recombinant IOFBP3 was tested for its effect on IGF-I-induced DNA synthesis in mesangial cells. Whether IGFBPs are involved in mediating the inhibitory effect of TGF-13 on TOP-I-stimulated DNA synthesis was also explored.
Methods

Materials
Porskolin was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Recombinant human TGP-1 was from R&D Systems, Inc. (Minneapolis, MN, USA) and recombinant human IGF-I and R3-IGF-I from GroPep (Adelaide, Australia). Recombinant human IGFBP3 was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY, USA). Rainbow molecular mass markers and radiolabeled IGF-I was obtained from Amersham (Arlington Heights, IL, USA). Centricon 10 concentrators were from Amicon (Danvers, MA, USA). RNAzol B was purchased from Cinna Biotex (Houston, TX, USA) and the Riboprobe Kit from Promega (Madison, WI, USA).
Antisense RNA probes. The probes for human IGFBP-2, -4, -5 and -6 were provided by Dr. Shimasaki (Whittier Institute, La Jolla, CA, USA) [11] . Each probe was derived from a eDNA fragment corresponding to part of the protein-coding region and cloned into pBluescript SKI. The IGFBP2 and IGFBP4 probes were synthesized from a StyI-EcoRV 382-bp and an EcoRIHindlil 505-bp fragment, respectively. The IGFBP5 and IGFBP6 probes were synthesized from a SacII-Saci 317-bp and a PstI-PstI 267-bp fragment, respectively. IGFBP-1 and -3 probes (provided by Dr. D. Powell, Baylor University, Waco, TX, USA) were synthesized from a PstI-PstI 369-bp and a PstI-EcoRI 535-bp fragment, respectively. The human 36B4 eDNA probe detects a ubiquitously expressed ribosomal phosphoprotein and was provided by Dr. P. Chambon (INSERM, Institut de la Sante et de Ia Recherche Medicale) [21] .
Cell culture
Human mesangial cells were cultured from glomeruli isolated by differential sieving as previously described [22] . Portions of normal renal cortex were obtained from kidneys judged unsuitable for transplantation. Epithelial cells were removed by digestion with collagenase. Glomerular cores were cultured in Waymouth's medium (GIBCO, Grand Island, NY, USA) supplemented with 15 mi Hepes, 0.6 U/mi insulin, 2 mrvi glutamine, 0.1 m nonessential amino acids, 1 m sodium pyruvate, antibiotic/ antifungal solution, and 17% fetal calf serum (FCS). Cells were used between passages three to ten.
RNase protection assay
To determine constitutive IGFBP-1 to -6 mRNA expression, total RNA was isolated from confluent cultures of mesangial cells maintained in Waymouth's medium with serum. Total RNA was isolated using RNAzoI B method. Concentrations were determined by spectrophotometry; integrity and quantitation was confirmed by visualizing ethidium bromide-stained 28S and 18S ribosomal bands on 1% agarose gels. For experiments designed to determine the effect of forskolin, IGF-I and TGF-/3 on IGFBP3 mRNA and protein, confluent MC were washed three times with serum-free, insulin-free (SFIF) medium and incubated 24 hours in the same medium. Fresh SFIF medium with or without forskolin, IGF-I, or TGF-J3 was added. Cell-free supernatants were collected at 8 and 24 hours and used for Western ligand blot analysis. Cells were also harvested for total RNA at these time points and at 72 hours. RNase protection assay was carried out as we have previously described [23] . 32P-labeled single-stranded RNA probes were synthesized in an antisense orientation using SP6, T7 or T3 RNA polymerase. After hybridization, samples were digested sequentially with RNases A and Ti and proteinase K. The products were analyzed by electrophoresis through a 7 M urea/6% acrylamide gel, followed by autoradiography.
Western ligand blot
Samples were concentrated 40-fold by ultrafiltration in Centricon 10 microconcentrators (10 kDa molecular wt cutoff). Ligand blotting with [1251]IGF-I was performed by the method of Hossenlopp et a! [24] as previously described [25] . Briefly, samples were electrophoresed through a 10% SDS-polyacryiamide gel. Separated Figure 4 represent the mean of at least three separate experiments SEM.
Results
IGFBP gene expression in human mesangial cells IGFBP mRNAs are expressed in the glomerulus. We examined the specific IGFBP mRNAs expressed by mesangial cells. Total RNA isolated from mesangial cells was hybridized with human IGFBP-i to -6 antisense RNA probes and analyzed using a sensitive RNase protection assay. Figure 1 demonstrates that mesangial cells constitutively express abundant levels of IGFBP-2 to -6 mRNAs, and to a lesser extent IGFBP1 mRNA. For each IGFBP analyzed, human breast carcinoma cell lines, MDA-MB 231 or MCF-7, were used as controls since they are known to express certain IGFBP mRNAs [26] . Autoradiograms show the expected protected fragment in both the control and mesangial cell total RNAs: 369-bp for IGFBP1; 325-bp for IGFBP2; 535-bp for IGFBP3; 505-bp for IGFBP4; 317-bp for IGFBP5 and 267-bp for IGFBP6. These fragments are specific and not observed in the tRNA lane.
Characterization of IGFBPs in mesangial cell conditioned medium
To determine if IGFBP mRNA expression is associated with the release of the corresponding IGFBPs, conditioned medium from mesangial cells was analyzed by ligand blotting with ['251 ]IGF-I. In Figure 2 , the first lane shows conditioned medium obtained from ovarian carcinoma cells (OVCAR-3) that contain IGFBPs of 24, 29 (not visualized), 32 kDa and a doublet at 46 kDa that correlate with IGFBP-4, -5, -2 and -3, respectively, as we have previously shown [25] . The constitutive release of IGFBPs from confluent mesangial cell cultures incubated under unstimulated, serum-free, insulin-free conditions is shown in lanes labeled control (8 and 24 hr). At eight hours, the 24 kDa species predominates with less abundant species of 29, 32, and 46 kDa. At Since IGFBP3 showed the strongest response to cytokines, experiments were carried out to determine if IGFBP3 is regulated at the level of mRNA abundance (Fig. 3) . RNA was isolated from the same experiment described in Figure 2 and from an additional the glomerulus [28] . The overall net effect of IGF-I would depend upon the relative abundance of each IGFBP that may interact in either a synergistic or opposing manner to modulate IGF action.
IGFBP-1, -2, -3 and -5 may either enhance or inhibit IGFmediated effects under varying incubation conditions, while IGFBP4 demonstrates only inhibitory activity. For IGFBPI, the biologic effect depends on the prevalence of phosphorylated and nonphosphorylated forms [29] . Although the effect of these IGFBPs in modulating IGF actions in renal disease are unknown, recent studies suggest that they play an important role. Induction of diabetes in rats by streptozotocin causes rapid renal hypertrophy that is preceded by a rise in kidney tissue IGF-I levels 24 to 48 hours after the onset of diabetes [7] . During this time, there is a coordinant increase in IGFBP3 and a 30 kDa IGFBP species in whole kidney extracts and an increase in IGFBP1 mRNA expression [30, 31] . By in situ hybridization, there is a predominant increase in IGFBP-l and -5 mRNA levels in the cortex and medulla, respectively [32] . The observation that treatment of rats with insulin, a potent inhibitor of IGFBP1, prevents the induction of IGFBPs and inhibits renal growth, suggests that IGFBP1 may be important for the initiation of renal hypertrophy [33, 34] .
The relative abundance of IGFBPs in the kidney is dependent, in part, on the regulation of each IGFBP by growth factors and hormones. In other systems, IGFBPs are regulated by agents that increase cAMP, IGF-I and TGF-/3, factors also implicated in the development of renal pathology [35] [36] [37] [38] . Mechanisms that govern the synthesis and secretion of each IGFBP are complex. IGFBP levels in mesangial cell conditioned medium may be influenced by several factors including differential transcription rate, post-translational modifications, alterations in membrane-associated fractions of certain IGFBPs and specific IGFBP proteases [39] . Under basal conditions, the relative ratio of IGFBPs in mesangial conditioned medium changed with time. IGFBP-2 and -3 protein levels increased while IGFBP-4 and -5 decreased between 8 to 24 hours. In the case of IGFBP-3, increased protein levels correlated with a time-dependent increase in IGFBP-3 mRNA abundance. In mesangial conditioned medium forskolin, IGF-I and TGF-13 induced distinct patterns of IGFBPs, with a prominent increase in IGFBP-3. Forskolin, a direct activator of adenylate cyclase, was used as a tool to determine the effect of increased cAMP levels on
IGFBPs. RNase protection assay demonstrated that forskolin increased IGFBP-3 mRNA levels. Previous studies have shown that IGFBP-3 is regulated in a tissue-and cell type-specific manner [40] . In MDBK epithelial cells and in fibroblasts, forskolin also increased IGFBP-3 mRNA and protein levels, whereas in osteoblasts, forskolin inhibited IGFBP-3 [18, 28, 41] .
IGF-I and TGF-f3 were potent inducers of IGFBP-3 protein release in mesangial cells; however, TGF-p, but not IGF-I, markedly increased IGFBP-3 mRNA levels. These findings suggest that IGFBP-3 is regulated by distinct mechanisms: forskolin and TGF-13 act by increasing de novo synthesis of IGFBP-3, while IGF-I acts by post-transcriptional mechanism(s). Similar results have been obtained in human fibroblasts [19] . In these cells, the effect of TGF-p on IGFBP-3 was at the level of mRNA abundance, while IGF-I altered the amount of surface bound [28] . It is also possible that IGF-I, like other agents, increases IGFBPs by inducing a specific protease inhibitor [42] . Whether one or a combination of these mechanisms play a role in IGF-I-mediated increase of IGFBP-3 protein released by mesangial cells requires further study.
Release of endogenous IGFBP-3 may influence the mitogenic effect of IGF-I on mesangial cells. In fibroblast cultures, simultaneous addition of IGFBP-3 with IGF-I inhibits the mitogenic action, while preincubation of the cells with IGFBP-3 prior to the addition of IGF-I potentiates IGF action [12] . Studies suggest that inhibition of IGF action is through interaction with soluble IGFBP-3, while potentiation occurs via cell surface-associated IGFBP-3 [43] . Co-incubation of IGFBP-3 with IGF-I or R3-IGF-I completely abrogated IGF-I, but not R3-IGF-I-induced mitogenesis in confluent mesangial cultures. These findings suggest that inhibition of IGF-I bioactivity is due to IGFBP-3 sequestering IGF-I, thereby preventing the interaction of IGF-I with its receptor. This is also supported by the observation that IGFBP-3 alone had no effect on mesangial cell DNA synthesis. In other systems, however, IGFBP-3 has been shown to have a direct inhibitory action on cell growth in the absence of IGF-I or -II [14] .
Induction of IGFBP-3 by TGF-f3 suggests that IGFBP-3 may mediate the inhibitory effect of TGF-f3 on IGF-I-induced DNA synthesis. Inhibition of both IGF-I and R3-IGF-I-induced DNA synthesis by TGF-13, however, indicates that the inhibitory effect of TGF-/3 is not mediated via an IGFBP. These results are in contrast to those reported by Yateman et al [20] , where TGF- 
